GLMD Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Valuation Metrics

The current forward P/E ratio for Galmed Pharmaceuticals Ltd (GLMD.O) is -0.85, compared to its 5-year average forward P/E of -1.22. For a more detailed relative valuation and DCF analysis to assess Galmed Pharmaceuticals Ltd 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-1.22

Current PE

-0.85

Overvalued PE

-0.19

Undervalued PE

-2.24

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

0.06

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

0.90

Undervalued EV/EBITDA

-0.78

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

0.00

Current PS

0.00

Overvalued PS

0.00

Undervalued PS

0.00

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

GLMD News & Events

Events Timeline

No data

News

9.0

12-08PRnewswire

Galmed Pharmaceuticals to Initiate Phase 1/2 Trial of Aramchol and Regorafenib in 2026

9.0

12-04Globenewswire

Galimedix Reports Excellent Phase 1 Results for GAL-101 with No Adverse Events

3.5

12-04PRnewswire

Galmed Secures New Patent for Aramchol, Extending Protection to 2042

People Also Watch

Frequently Asked Questions

What is Galmed Pharmaceuticals Ltd (GLMD) stock price today?

The current price of GLMD is 0.9707 USD — it has decreased -7.52 % in the last trading day.

What is Galmed Pharmaceuticals Ltd (GLMD)'s business?

Galmed Pharmaceuticals Ltd. is an Israel-based biopharmaceutical company dedicated to the development of therapeutics for the treatment of liver diseases. The Company is focused its research and development efforts on addressing unmet medical needs in the field of liver health. The Company's flagship product is Aramchol, a first-in-class synthetic fatty acid-bile acid conjugate molecule. Aramchol is aimed to be effective in the treatment of non-alcoholic steatohepatitis (NASH) in patients who are overweight or obese and have prediabetes or type II diabetes mellitus. The Company's drug aims to be efficient treatment of NASH, a chronic liver disease characterized by fat accumulation, inflammation, and fibrosis, which can lead to cirrhosis and liver cancer if left untreated.

What is the price predicton of GLMD Stock?

Wall Street analysts forecast GLMD stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for GLMD is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Galmed Pharmaceuticals Ltd (GLMD)'s revenue for the last quarter?

Galmed Pharmaceuticals Ltd revenue for the last quarter amounts to 0.00 USD, decreased % YoY.

What is Galmed Pharmaceuticals Ltd (GLMD)'s earnings per share (EPS) for the last quarter?

Galmed Pharmaceuticals Ltd. EPS for the last quarter amounts to -0.35 USD, decreased -84.85 % YoY.

What changes have occurred in the market's expectations for Galmed Pharmaceuticals Ltd (GLMD)'s fundamentals?

The market is revising No Change the revenue expectations for Galmed Pharmaceuticals Ltd. (GLMD) for FY2025, with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by -34.41%.

How many employees does Galmed Pharmaceuticals Ltd (GLMD). have?

Galmed Pharmaceuticals Ltd (GLMD) has 3 emplpoyees as of December 16 2025.

What is Galmed Pharmaceuticals Ltd (GLMD) market cap?

Today GLMD has the market capitalization of 5.32M USD.